[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimers-dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimers-dementia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,75,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100612156","feasibility-of-wearables-in-dementia-care-in-rural-taiwan-100612156",false,"NCT07249918","Feasibility of Wearables in Dementia Care in Rural Taiwan","Facilitating the Measurement and Treatment of the Behavioral Symptoms of Dementia (BPSD) and Understanding Caregiver Burden Using Wearable Devices in Rural Taiwan - A Dyadic Feasibility Pilot Study","Inclusion Criteria:\n\n* For participants with dementia:\n\n  1. Clinical diagnosis of probable Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD, based on established diagnostic criteria.\n  2. Presence of at least one prominent behavioral or psychological symptom of dementia (BPSD), including depression, agitation, apathy, or nighttime sleep disturbance.\n  3. Prominent is defined as:\n\n     NPI single-item score ≥ 4 (severity × frequency), or NPI-Q severity score ≥ 2, or PSQI total score ≥ 5 (if sleep disturbance is the main symptom).\n  4. Stable living arrangement or care environment for at least two weeks before enrollment.\n  5. If receiving any pharmacological or non-pharmacological treatments for BPSD, the dosage and frequency must have remained stable for at least two weeks prior to study participation.\n  6. Able and willing to provide informed consent; for those lacking decision-making capacity, consent must be obtained from a legally authorized representative.\n* For primary caregivers:\n\n  1. Adult primary caregiver of the enrolled participant.\n  2. If receiving treatment for caregiver stress, the dosage and frequency must have been stable for at least two weeks before enrollment.\n  3. Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Any medical condition that may increase risk during participation, including:\n\n  1. Retinal disease, active use of photosensitizing medications, recent ocular surgery (within 4 weeks), or photosensitivity disorders (e.g., epilepsy).\n  2. Unstable physical or mental condition deemed unsuitable by investigators, such as acute delirium or active respiratory infection (including COVID-19)",true,"ALL",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Taiwan is becoming a super-aged society, and more older adults are living with Alzheimer's disease. Many people with Alzheimer's experience behavioral and psychological symptoms, such as agitation, sleep problems, or mood changes. These symptoms often lower their quality of life and increase stress for their family caregivers.\n\nThis study will test two wearable devices in people with Alzheimer's and their caregivers. One device, called Geneactiv, is a wristwatch that tracks daily activity and sleep. The other device, called Re-Timer, is a light therapy eyewear that may help improve sleep and mood. Researchers will look at how easy the devices are to use, whether participants are willing to wear them for several weeks, and whether the light therapy helps reduce sleep problems or caregiver stress.\n\nThe study will also compare information from questionnaires with information collected by the devices. The results may help researchers design future studies using wearable tools to better support people living with dementia and their caregivers.",[26,27,28,29,30],"Alzheimer's Dementia","Neuropsychiatric Symptoms Related to Neurodegenerative Disease","Wearable Devices","Caregiver Burden of People With Dementia","Circadian Rhythm",[32,33,34,35,36],"Wearable device","behavioural and psychological symptoms of dementia (BPSD)","Sleep","Alzheimer's dementia","Caregiver Burden","RECRUITING","2026-02-09",{"date":40,"type":41},"2026-02-11","ACTUAL",{"date":43,"type":41},"2025-11-18",{"date":45,"type":20},"2026-12-31",{"name":47,"class":48},"China Medical University Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":49},"100557177","phase-3-phase-3-clinical-trial-of-wujia-yizhi-granules-in-the-treatment-of-mild-to-moderate-alzheimers-dementia-syndrome-of-deficiency-of-spleen-and-kidney-100557177","NCT06534723","Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)","A 12-month Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney).","Inclusion Criteria:\n\n1. Male or female, age range : 50 - 80 years old.\n2. Informed consent signed and dated by patient or legal representative.\n3. The participants are mild-to-moderate AD patients who meet the diagnostic criteria for AD proposed by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in 2018 and have a disease course of more than 6 months. If participants lack previous pathological evidence or biomarkers of Alzheimer's dementia, they must have evidence of β-amyloid deposition biomarkers during screening (PET with abnormal amyloid deposition or low cerebrospinal fluid Aβ 42 and Aβ 42\u002FAβ 40 ratio).\n4. MMSE score 11 to 26;CDR-GS score 1 to 2 。\n\nExclusion Criteria:\n\n1. Participants with non AD induced memory and cognitive impairment, such as diagnosis of other types of dementia, including but not limited to mixed dementia (AD VaD), vascular dementia (VD), Parkinson's disease dementia (PDD), Lewy body dementia (DLB), Huntington's disease related dementia, frontotemporal lobe dementia (FTD), etc; Endocrine system disorders (such as thyroid diseases, parathyroid diseases) and dementia caused by folate, vitamin B12 deficiency, or any other reason; Existence of consciousness disorders, etc.\n2. Participants have a history of epileptic seizures.\n3. Participants are psychiatric patients, including but not limited to schizophrenia, affective schizophrenic disorder, bipolar disorder, or delirium.\n4. HAMD-17 score ≥ 17 points.\n5. HAMA score ≥ 14 points.\n6. Participants were taking antidepressants, anxieties, and antipsychotic drugs during screening.\n7. HIS score ≥ 4 points..","50 Years","80 Years",{"count":60,"type":20},570,[62],"PHASE3","This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia",[26],"2025-12-25",{"date":67,"type":41},"2025-12-29",{"date":69,"type":41},"2024-08-20",{"date":71,"type":20},"2026-12-01",{"name":73,"class":74},"Sichuan Jishengtang Pharmaceutical Co., Ltd.","INDUSTRY",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100556300","electroacupuncture-treatment-of-behavioral-and-psycological-symptoms-in-patients-with-alzheimers-disease-100556300","NCT06523309","Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease","Prospective Registry of Electroacupuncture Treatment for Patients With Different Behavioral and Psycological Symptoms of Alzheimer's Disease","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for AD in the NIA-AA standard;\n2. Clinical dementia rating scale ≤2 points;\n3. Accompanied by at least one psychobehavioral symptom, NPI：frequency × degree ≥1 point;\n4. Sign informed consent.\n\nExclusion Criteria:\n\n1.There are contraindications for acupuncture treatment, such as the tendency of acupoint bleeding or allergy to metal",{"count":83,"type":20},1000,"OBSERVATIONAL","This study aims to establish a prospective case registration research platform for electroacupuncture in treating behavioral and psychological symptoms in patients with mild to moderate Alzheimer's disease, and to investigate the dose-effect relationship and cost-effectiveness of electroacupuncture for these symptoms.",[87,26],"BPSD (Behavioral and Psycological Symptoms of Dementia)","NOT_YET_RECRUITING","2024-07-25",{"date":91,"type":41},"2024-07-26",{"date":93,"type":20},"2024-07-30",{"date":95,"type":20},"2027-10-31",{"name":97,"class":48},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",7,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":98},"100554197","electroacupuncture-for-the-treatment-of-agitated-symptoms-of-alzheimers-disease-100554197","NCT06495957","Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease","Evaluation of Therapeutic Effect and Brain Mechanism of Electroacupuncture in Treating Agitation Symptoms of Alzheimer's Disease","Inclusion Criteria:\n\n1. Meet the revised draft diagnostic criteria for Alzheimer's disease published by the Alzheimer's Association in 2023\n2. Meet the 2023 IPA definition of agitated symptoms of cognitive impairment\n3. Cohen Mansfield Agitation Inventory (CMAI)≥45 points\n4. Have been on stable anti-AD medication (cholinesterase inhibitors, etc.) for more than 1 month\n5. If taking antipsychotics, the medication regimen for agitation (antipsychotics) is stable for 1 month prior to randomization\n6. Subject and legal guardian and caregiver sign informed consent.\n\nExclusion Criteria:\n\n1. There are contraindications for acupuncture treatment, such as the tendency of acupoint bleeding or allergy to metal\n2. Received electroacupuncture treatment in the past 2 weeks\n3. At the time of the screening, participants are participating in other clinical trials or planned to participate in other clinical trials in the next 17 weeks.",{"count":107,"type":20},224,[23],"The purpose of this study is to evaluate the efficacy of electroacupuncture in the treatment of agitation symptoms in patients with Alzheimer's disease (AD). Meanwhile the study aims to explore the brain central mechanism of electroacupuncture in the treatment of agitation symptoms in patients with AD by using resting state functional magnetic resonance technology.",[111,26],"Agitation Associated With Alzheimer's Dementia","2024-07-03",{"date":114,"type":41},"2024-07-11",{"date":116,"type":20},"2024-07-20",{"date":95,"type":20},{"name":97,"class":48}]